Precigen (NASDAQ:PGEN) CFO Sells $165,140.38 in Stock

Precigen, Inc. (NASDAQ:PGEN) CFO Harry Jr. Thomasian sold 28,571 shares of the company’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $5.78, for a total transaction of $165,140.38. Following the transaction, the chief financial officer owned 525,964 shares in the company, valued at $3,040,071.92. This represents a 5.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harry Jr. Thomasian also recently made the following trade(s):

• On Wednesday, July 1st, Harry Jr. Thomasian sold 171,429 shares of Precigen stock. The shares were sold at an average price of $5.53, for a total value of $948,002.37.
• On Thursday, May 28th, Harry Jr. Thomasian sold 41,884 shares of Precigen stock. The shares were sold at an average price of $4.36, for a total value of $182,614.24.

Precigen Price Performance

PGEN stock opened at $5.64 on Friday. The stock’s 50 day simple moving average is $4.49 and its 200 day simple moving average is $4.25. Precigen, Inc. has a fifty-two week low of $1.47 and a fifty-two week high of $6.04. The company has a debt-to-equity ratio of 4.62, a quick ratio of 4.12 and a current ratio of 4.82. The company has a market cap of $2.01 billion, a P/E ratio of -4.78 and a beta of 1.00.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.01. Precigen had a positive return on equity of 717.50% and a negative net margin of 646.99%.The business had revenue of $23.25 million for the quarter, compared to analyst estimates of $20.81 million. On average, research analysts expect that Precigen, Inc. will post -0.02 earnings per share for the current fiscal year.

Institutional Trading of Precigen

Several institutional investors and hedge funds have recently made changes to their positions in the company. State of Wyoming bought a new position in shares of Precigen during the first quarter valued at about $27,000. NBC Securities Inc. bought a new stake in Precigen in the 4th quarter worth about $38,000. Mason Investment Advisory Services Inc. bought a new stake in Precigen in the 4th quarter worth about $42,000. Abel Hall LLC purchased a new stake in Precigen in the 4th quarter valued at about $44,000. Finally, Royal Bank of Canada increased its stake in Precigen by 102.6% in the 1st quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 5,426 shares during the last quarter. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Analyst Ratings Changes

PGEN has been the subject of several research reports. Wall Street Zen downgraded shares of Precigen from a “buy” rating to a “hold” rating in a research report on Sunday, May 31st. Citigroup restated an “outperform” rating on shares of Precigen in a report on Thursday, May 14th. HC Wainwright raised their price objective on shares of Precigen from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, May 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a report on Tuesday, April 21st. Finally, Zacks Research upgraded shares of Precigen from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $12.50.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.